Dicing the Disease with Dicer: The Implications of Dicer Ribonuclease in Human Pathologies

Int J Mol Sci. 2020 Sep 30;21(19):7223. doi: 10.3390/ijms21197223.

Abstract

Gene expression dictates fundamental cellular processes and its de-regulation leads to pathological conditions. A key contributor to the fine-tuning of gene expression is Dicer, an RNA-binding protein (RBPs) that forms complexes and affects transcription by acting at the post-transcriptional level via the targeting of mRNAs by Dicer-produced small non-coding RNAs. This review aims to present the contribution of Dicer protein in a wide spectrum of human pathological conditions, including cancer, neurological, autoimmune, reproductive and cardiovascular diseases, as well as viral infections. Germline mutations of Dicer have been linked to Dicer1 syndrome, a rare genetic disorder that predisposes to the development of both benign and malignant tumors, but the exact correlation of Dicer protein expression within the different cancer types is unclear, and there are contradictions in the data. Downregulation of Dicer is related to Geographic atrophy (GA), a severe eye-disease that is a leading cause of blindness in industrialized countries, as well as to psychiatric and neurological diseases such as depression and Parkinson's disease, respectively. Both loss and upregulation of Dicer protein expression is implicated in severe autoimmune disorders, including psoriasis, ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis and autoimmune thyroid diseases. Loss of Dicer contributes to cardiovascular diseases and causes defective germ cell differentiation and reproductive system abnormalities in both sexes. Dicer can also act as a strong antiviral with a crucial role in RNA-based antiviral immunity. In conclusion, Dicer is an essential enzyme for the maintenance of physiology due to its pivotal role in several cellular processes, and its loss or aberrant expression contributes to the development of severe human diseases. Further exploitation is required for the development of novel, more effective Dicer-based diagnostic and therapeutic strategies, with the goal of new clinical benefits and better quality of life for patients.

Keywords: Dicer ribonuclease; Dicer1 syndrome; RISC; RNA binding proteins; autoimmune diseases; cancer; cardiovascular diseases; human diseases; infertility; microRNAs; neurological disorders; post-transcriptional regulation; viral infection.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / genetics
  • Cardiovascular Diseases / therapy
  • Cell Differentiation / genetics
  • DEAD-box RNA Helicases / genetics*
  • Humans
  • MicroRNAs / genetics*
  • Neoplasms / genetics
  • Neoplasms / therapy
  • Nervous System Diseases / genetics
  • Nervous System Diseases / therapy
  • RNA, Messenger / genetics*
  • RNA, Small Untranslated / genetics*
  • Ribonuclease III / genetics*
  • Virus Diseases / genetics
  • Virus Diseases / therapy

Substances

  • MicroRNAs
  • RNA, Messenger
  • RNA, Small Untranslated
  • DICER1 protein, human
  • Ribonuclease III
  • DEAD-box RNA Helicases

Grants and funding